NGL Fine-ChemNSE:NGLFINE -3.37%78 Current Ratio is 1.84 as of Mar. 2026, which is 9% below its 10-year median of 2.03. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,812.79 (Fairly Valued). The stock has 8 warning signs investors should review. Among 997 Drug Manufacturers companies, NGL Fine-Chem ranks worse than 54.26% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. NGL Fine-Chem's current ratio for the quarter that ended in Mar. 2026 was 1.84.
NGL Fine-Chem has a current ratio of 1.84. It generally indicates good short-term financial strength.
The historical rank and industry rank for NGL Fine-Chem's Current Ratio or its related term are showing as below:
NSE:NGLFINE'
s Current Ratio Range Over the Past 10 Years
Min: 1.39 Med: 2.03 Max: 2.98
Current: 1.84
During the past 13 years, NGL Fine-Chem's highest Current Ratio was 2.98. The lowest was 1.39. And the median was 2.03.
NSE:NGLFINE's Current Ratio is ranked worse than 54.26% of 997
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:NGLFINE: 1.84
NGL Fine-Chem (NSE:NGLFINE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
NGL Fine-Chem Current Ratio Related Terms
NGL Fine-Chem Current Ratio Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Current Ratio distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a Current Ratio of 1.84 as of Mar. 2026. This is near median its historical median of 2.03. Over the past decade, NGL Fine-Chem's Current Ratio has ranged from 1.39 to 2.98. According to the industry distribution chart, NGL Fine-Chem ranks #541 out of 997 companies in the Drug Manufacturers industry, placing it in the top 54.3%.
Is NGL Fine-Chem's Current Ratio too high?
NGL Fine-Chem's current Current Ratio of 1.84 is near median its 10-year median of 2.03. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 2.98. The Drug Manufacturers industry median Current Ratio is 2.00. NGL Fine-Chem's value of 1.84 is 8% below this industry median. Based on the distribution chart, NGL Fine-Chem ranks #541 out of 997 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #541 out of 997 companies for Current Ratio. This places NGL Fine-Chem in the lower half of its industry. The industry median Current Ratio is 2.00. NGL Fine-Chem's value of 1.84 is 8% below this benchmark. Historically, NGL Fine-Chem's own Current Ratio has ranged from 1.39 to 2.98 over the past decade. While the company's 10-year median is 2.03 vs. the industry median of 2.00, NGL Fine-Chem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Current Ratio of 1.84 is 8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Current Ratio is 1.84, which is near median its own 10-year median of 2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,812.79, compared to a current price of ₹3,002.70 — trading 6.8% above its estimated fair value. The current Current Ratio is 1.84, which is near median its 10-year median of 2.03 and 8% below the Drug Manufacturers industry median of 2.00. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Current Ratio is 1.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,002.70 is trading 6.8% above its estimated GF Value™ of ₹2,812.79.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
Current Ratio: 1.84 (near median its 10-year median of 2.03)
GF Value™: ₹2,812.79 vs. price of ₹3,002.70 (6.8% above fair value)
Industry Position: 8% below the Drug Manufacturers median (#541 of 997)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
